A Phase 2 interventional study of GSK1278863 and Placebo in Anaemia, sponsored by GlaxoSmithKline. Completed at 21 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-02-12.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.
Among the 30 studies testing GSK1278863 in Anemia, this one is the 14th largest by enrollment, is one of 3 that started in 2013, is one of 10 in phase 2, and was the 8th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:
GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 76 across the 30 interventional studies. Of the 29 that completed or were terminated, 23 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 30 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
35 studies in Anemia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 35 finished, 25 (71%) have results posted.
Among the 35 studies in Anemia by GlaxoSmithKline, this one is the 15th largest by enrollment, is one of 3 that started in 2013, is one of 11 in phase 2, and was the 13th registered.
GlaxoSmithKline’s Anemia studies by the year they started, since 2006.
1 of the studies testing GSK1278863 in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300111Phase 3Qilu Pharmaceutical Co., Ltd.A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing GSK1278863 in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 35 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to characterize the relationship between dose of GSK1278863 and hemoglobin (Hgb) response in hemodialysis-dependent (HDD) subjects with anemia associated with chronic kidney disease (CKD). It is anticipated that the data generated will enable selection of the starting dose(s) and optimize dose adjustment regimen(s) for Phase 3 clinical trials. This study will consist of a screening phase of 3-9 weeks, a 4-week treatment phase and a follow-up visit approximately 4 weeks after completing treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive GSK1278863 4 mg once daily for 4 weeks
Drug: GSK1278863
Subjects will receive GSK1278863 6 mg once daily for 4 weeks
Drug: GSK1278863
Subjects will receive GSK1278863 8 mg once daily for 4 weeks
Drug: GSK1278863
Subjects will receive GSK1278863 10 mg once daily for 4 weeks
Drug: GSK1278863
Subjects will receive placebo once daily for 4 weeks
Drug: Placebo
GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.
Film coated tablets of GSK1278863 matching placebo for oral administration.
Change From Baseline (CFB) in Hemaglobin (Hgb) at Week 4
Baseline was defined as the value on Day 1. CFB was calculated by subtracting the baseline value from the post-dose value at Week 4. To model the dose-response relationship a four-parameter Emax model was used. E0 is the expected Hgb change from Baseline for a participant receiving placebo and experiencing the average Hgb Baseline observed in the study. Emax is the expected Hgb change from Baseline for a participant receiving the highest dose above which no further increase in response can be achieved. ED50 is the dose that attains the intermediate response. Gamma is the slope parameter. Minimal Effective Dose (MED) is defined as the smallest dose that achieves a placebo-corrected change of 0.5 g/dL over Week 4. Target dose (TD) is defined as the dose that achieves a placebo-corrected 1.0 g/dL change over Week 4. Maximum Acceptable Dose (MAD) is defined as the dose that achieves a placebo-corrected 2.0 g/dL change over Week 4.
Time frame: Baseline (Day 1) and Week 4
CFB in Hgb Upto Week 8
Hgb assessments were performed at Baseline, Week 1, Week 2, Week 3, W eek4/Early withdrawal and Week 8 (follow-up) based on central laboratory (Quest diagnosis). Baseline was defined as the value on Day 1. CFB was calculated by subtracting the Baseline value from the post-dose value at Week 4.
Time frame: Baseline (Day 1) Upto Week 8
Number of Participants Who Achieved Hgb Response at Week 4
Hgb response was defined as achieving an increase of at least 0.5 g/dL, 1.0 g/dL, 1.5 g/dL, and 2.0 g/dL in Hgb. The number of participants with Hgb response: Hgb increase \<-1.0, Hgb increase -1.0 -\< -0.5, Hgb increase -0.5 -\< 0.5, Hgb increase 0.5 -\< 1.0 and Hgb increase \>=1.0 have been presented.
Time frame: Week 4
Percentage of Participants Who Achieved Hgb Response at Week 4
Hgb response was defined as achieving an increase of at least 0.5 g/dL, 1.0 g/dL, 1.5 g/dL, and 2.0 g/dL in Hgb. The percentage of participants with Hgb response: Hgb increase \<-1.0, Hgb increase -1.0 -\< -0.5, Hgb increase -0.5 -\< 0.5, Hgb increase 0.5 -\< 1.0 and Hgb increase \>=1.0 have been presented.
Time frame: Week 4
Number of Participants Who Reached Pre-defined Hgb Stopping Criteria
Hgb stopping criteria was defined as: (1) Hgb \<7.5 g/dL (2) 7.5 \<= Hgb \<1 3.0 g/dL and \>2 g/dL Hgb change over 2W (3) Hgb \>=13.0 g/dL. The number of participants who reached pre-defined Hgb stopping criteria have been presented.
Time frame: Upto Week 4
Maximum Observed CFB in Erythropoietin (EPO) Upto Week 4
Blood samples for EPO were collected on Day 1 (pre-dose), Week 2 (collected approx 6-12 hours post-dose on arrival and after 1, 2 and 3 hours) and Week 4 (pre-dose and 3 hours post-dose). Maximum observed value meant maximum value between Week 1 and Week 4. Baseline was defined as the value on Day 1. Maximum observed CFB was calculated by subtracting the Baseline value from the maximum observed value between Week 1 and Week 4.
Time frame: Baseline (Day 1) Upto Week 4
Maximum Observed Percent CFB in Peak Vascular Endothelial Growth Factor (VEGF) Upto Week 4
Blood samples for VEGF were collected on Day 1 (pre-dose), Week 2 (collected approximately 6-12 hours post-dose on arrival and after 1, 2 and 3 hours) and Week 4 (pre-dose and 3 hours post-dose). Maximum observed value meant maximum value between Week 1 and Week 4. Baseline was defined as the value on Day 1. Maximum observed percent CFB was calculated as 100 multiplied by the maximum observed exponential mean change on a log scale minus 1.
Time frame: Baseline (Day 1) Upto Week 4
Percent CFB in Hepcidine Upto Week 4
Blood samples for hepcidine were collected on Day 1 (pre-dose), Week 2 (collected approximately 6-12 hours post-dose) and Week 4 (pre-dose). Baseline was defined as the value on Day 1. Percent CFB was calculated as 100 multiplied by the exponential mean change on a log scale minus 1.
Time frame: Baseline (Day 1) Upto Week 4
CFB in Ferritin at Week 4
Ferritin was used as marker of iron metabolism and utilization. Baseline was defined as the value on Day 1. CFB was calculated by subtracting the Baseline value from the post dose value at Week 4.
Time frame: Baseline (Day 1) and Week 4
CFB in Total Iron Binding Capacity [TIBC], Unbound Iron Binding Capacity [UIBC] and Iron at Week 4
TIBC, UIBC and Iron were used as marker of iron metabolism and utilization. Baseline was defined as the value on Day 1. CFB was calculated by subtracting the Baseline value from the post-dose value at Week 4.
Time frame: Baseline (Day 1) and Week 4
CFB in Transferrin at Week 4
Transferrin was used as marker of iron metabolism and utilization. Baseline was defined as the value on Day 1. CFB was calculated by subtracting the Baseline value from the post-dose value at Week 4.
Time frame: Baseline (Day 1) and Week 4
Percent CFB in Transferrin Saturation (TS) at Week 4
TS was used as marker of iron metabolism and utilization. Baseline was defined as the value on Day 1. Percent CFB was calculated as 100 multiplied by the exponential mean change on a log scale minus 1.
Time frame: Baseline (Day 1) and Week 4
Plasma Pharmacokinetic Concentration of GSK1278863 and Metabolites (M) at Week 4
Blood samples for plasma pharmacokinetic analysis were collected at Week 4 (pre-dose, 1, 2, 3 hours post-dose). Individual plasma GSK1278863 and M-GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531401, GSK2531403 concentrations have been presented.
Time frame: Week 4
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) on Therapy
An AE is defined as any untoward medical occurrence in clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A SAE is defined as any AE which results in death; is life-threatening; requires participant hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event.
Time frame: Upto Week 4
Number of Participants With Chemistry and Hematology Data of Potential Clinical Importance (PCI) Upto Week 4
The PCI range was as follows: alkaline phosphates \>= 3 times upper limit of normal range \[ULRR\]), potassium (\>0.5 millimoles/liter below the LLRR or \>1.0 millimoles/liter above the ULRR), phosphate (\>0.323 millimoles/liter above ULRR or below lower limit reference range \[LLRR\]), glucose (\<3.9 or \>22 millimoles/liter), magnesium (\<LLRR or \> 0.3 milimoles/liter above ULRR), lymphocytes \<0.5x LLRR, neutrophils (\<0.5 times LLRR), platelets (80 or \>500 times giga/liter), platelets (80 or \>500 times giga/liter) and leukocytes \>1 x giga/liter below the LLRR or \>5 x GI/L above the ULRR. The participants who had PCI values higher and lower than the reference range have been presented.
Time frame: Upto Week 4
Number of Participants With Vital Signs Parameters Systolic and Diastolic Blood Pressure (SBP,DBP) of PCI Upto Week 4
Vital signs SBP and DBP were recorded pre-dialysis and post-dialysis. Measurements were taken from the participant while in a seated position or semi-supine in the dialysis chair. PCI range for SBP was \< 85 or \> 170 and for DBP was \< 45 or \> 100 millimeters of mercury. Participant's with values high and low from the PCI range have been presented.
Time frame: Upto Week 4
Number of Participants With Vital Sign Parameter Heart Rate (HR) of PCI Upto Week 4
Vital sign HR was recorded pre-dialysis and post-dialysis. Measurements were taken from the participant while in a seated position or semi-supine in the dialysis chair. PCI range for HR was \< 40 or \> 110 beats per minute. Participant's with values higher than the PCI range have been presented.
Time frame: Upto Week 4
Number of Participants With Abnormal Electrocardiogram (ECG) Findings Upto Week 4
Full 12-lead ECGs included heart rate, PR, QRS, QT and QTc intervals. Measurements were taken from the participant while in a supine position. ECGs were performed consistently either before or after dialysis throughout the study. ECG abnormalities characterized as abnormal-not clinically significant (A-NCS) and abnormal-clinically significant (A-CS) upto W4 have been presented.
Time frame: Upto Week 4
This was a study to evaluate dose-response of GSK1278863 in approximately 95 Japanese Hemodialysis-dependent (HDD) participants with anemia associated with Chronic Kidney Disease (CKD) conducted across 21 centers in Japan from 05 November 2013 to 06 August 2014.
| Milestone | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| Started | 19 | 19 | 20 | 19 | 20 |
| Completed | 13 | 18 | 20 | 17 | 18 |
| Not completed | 6 | 1 | 0 | 2 | 2 |
| Withdrew: Adverse event | 1 | 0 | 0 | 1 | 1 |
| Withdrew: Protocol violation | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol defined stopping criteria | 2 | 0 | 0 | 1 | 1 |
| Withdrew: Physician decision | 2 | 0 | 0 | 0 | 0 |
Baseline was defined as the value on Day 1. CFB was calculated by subtracting the baseline value from the post-dose value at Week 4. To model the dose-response relationship a four-parameter Emax model was used. E0 is the expected Hgb change from Baseline for a participant receiving placebo and experiencing the average Hgb Baseline observed in the study. Emax is the expected Hgb change from Baseline for a participant receiving the highest dose above which no further increase in response can be achieved. ED50 is the dose that attains the intermediate response. Gamma is the slope parameter. Minimal Effective Dose (MED) is defined as the smallest dose that achieves a placebo-corrected change of 0.5 g/dL over Week 4. Target dose (TD) is defined as the dose that achieves a placebo-corrected 1.0 g/dL change over Week 4. Maximum Acceptable Dose (MAD) is defined as the dose that achieves a placebo-corrected 2.0 g/dL change over Week 4.
| grams/deciliter (g/dL) | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| Change From Baseline (CFB) in Hemaglobin (Hgb) at Week 4 | -1.52 ± 0.212 | -0.29 ± 0.200 | -0.02 ± 0.193 | 0.60 ± 0.202 | 0.92 ± 0.196 |
Hgb assessments were performed at Baseline, Week 1, Week 2, Week 3, W eek4/Early withdrawal and Week 8 (follow-up) based on central laboratory (Quest diagnosis). Baseline was defined as the value on Day 1. CFB was calculated by subtracting the Baseline value from the post-dose value at Week 4.
| g/dL | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| CFB at Week 1 | -0.34 ± 0.485 | -0.23 ± 0.374 | -0.35 ± 0.462 | -0.31 ± 0.481 | -0.17 ± 0.318 |
| CFB at Week 2 | -0.79 ± 0.538 | -0.32 ± 0.449 | -0.32 ± 0.780 | 0.01 ± 0.586 | 0.24 ± 0.353 |
| CFB at Week 3 | -1.14 ± 0.743 | -0.42 ± 0.658 | -0.34 ± 0.776 | 0.21 ± 0.692 | 0.37 ± 0.471 |
| CFB at Week 4 | -1.31 ± 0.923 | -0.33 ± 0.754 | -0.22 ± 1.008 | 0.34 ± 1.069 | 0.51 ± 0.679 |
| CFB at Week 8, Follow-up | -1.20 ± 0.997 | -0.90 ± 0.953 | -0.38 ± 0.526 | -0.21 ± 1.218 | -0.34 ± 0.691 |
Hgb response was defined as achieving an increase of at least 0.5 g/dL, 1.0 g/dL, 1.5 g/dL, and 2.0 g/dL in Hgb. The number of participants with Hgb response: Hgb increase \<-1.0, Hgb increase -1.0 -\< -0.5, Hgb increase -0.5 -\< 0.5, Hgb increase 0.5 -\< 1.0 and Hgb increase \>=1.0 have been presented.
| Participants | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| Hgb increase <-1.0 | 11 | 4 | 3 | 0 | 0 |
| Hgb increase -1.0 -< -0.5 | 2 | 2 | 2 | 1 | 0 |
| Hgb increase -0.5 -< 0.5 | 2 | 10 | 8 | 7 | 6 |
| Hgb increase 0.5 -< 1.0 | 0 | 1 | 3 | 4 | 4 |
| Hgb increase >=1.0 | 0 | 1 | 4 | 6 | 9 |
Hgb response was defined as achieving an increase of at least 0.5 g/dL, 1.0 g/dL, 1.5 g/dL, and 2.0 g/dL in Hgb. The percentage of participants with Hgb response: Hgb increase \<-1.0, Hgb increase -1.0 -\< -0.5, Hgb increase -0.5 -\< 0.5, Hgb increase 0.5 -\< 1.0 and Hgb increase \>=1.0 have been presented.
| Percentage of participants | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| Hgb increase <-1.0 | 73 | 22 | 15 | — | — |
| Hgb increase -1.0 -< -0.5 | 13 | 11 | 10 | 6 | — |
| Hgb increase -0.5 -< 0.5 | 13 | 56 | 40 | 39 | 32 |
| Hgb increase 0.5 -< 1.0 | — | 6 | 15 | 22 | 21 |
| Hgb increase >=1.0 | — | 6 | 20 | 33 | 47 |
Hgb stopping criteria was defined as: (1) Hgb \<7.5 g/dL (2) 7.5 \<= Hgb \<1 3.0 g/dL and \>2 g/dL Hgb change over 2W (3) Hgb \>=13.0 g/dL. The number of participants who reached pre-defined Hgb stopping criteria have been presented.
| Participants | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| < 7.5 | 2 | 0 | 0 | 0 | 0 |
| 7..5 -< 13.0 and >2 g/dL change | 0 | 0 | 0 | 2 | 1 |
Blood samples for EPO were collected on Day 1 (pre-dose), Week 2 (collected approx 6-12 hours post-dose on arrival and after 1, 2 and 3 hours) and Week 4 (pre-dose and 3 hours post-dose). Maximum observed value meant maximum value between Week 1 and Week 4. Baseline was defined as the value on Day 1. Maximum observed CFB was calculated by subtracting the Baseline value from the maximum observed value between Week 1 and Week 4.
| International units/liter | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| Maximum Observed CFB in Erythropoietin (EPO) Upto Week 4 | 6.658 ± 4.5414 | 34.951 ± 28.2718 | 94.518 ± 122.4985 | 151.012 ± 151.2964 | 173.446 ± 226.7241 |
Blood samples for VEGF were collected on Day 1 (pre-dose), Week 2 (collected approximately 6-12 hours post-dose on arrival and after 1, 2 and 3 hours) and Week 4 (pre-dose and 3 hours post-dose). Maximum observed value meant maximum value between Week 1 and Week 4. Baseline was defined as the value on Day 1. Maximum observed percent CFB was calculated as 100 multiplied by the maximum observed exponential mean change on a log scale minus 1.
| Percent change | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| Maximum Observed Percent CFB in Peak Vascular Endothelial Growth Factor (VEGF) Upto Week 4 | 45.05 (1.00 to 108.32) | 18.78 (4.38 to 35.17) | 18.94 (8.19 to 30.75) | 27.70 (6.07 to 53.73) | 44.29 (14.44 to 81.94) |
Blood samples for hepcidine were collected on Day 1 (pre-dose), Week 2 (collected approximately 6-12 hours post-dose) and Week 4 (pre-dose). Baseline was defined as the value on Day 1. Percent CFB was calculated as 100 multiplied by the exponential mean change on a log scale minus 1.
| Percent change | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| Percent CFB in hepcidine,Week 2 | 9.98 (-0.66 to 21.76) | -50.71 (-59.75 to -39.65) | -64.90 (-73.55 to -53.42) | -66.29 (-73.38 to -57.30) | -73.52 (-78.79 to -66.94) |
| Percent CFB in hepcidine,Week 4 | 3.26 (-9.18 to 17.42) | -60.34 (-67.40 to -51.76) | -69.66 (-77.38 to -59.30) | -69.06 (-77.57 to -57.31) | -77.71 (-82.08 to -72.28) |
Ferritin was used as marker of iron metabolism and utilization. Baseline was defined as the value on Day 1. CFB was calculated by subtracting the Baseline value from the post dose value at Week 4.
| micrograms/liter | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| CFB in Ferritin at Week 4 | 4.7 ± 114.79 | -50.6 ± 40.28 | -78.3 ± 52.32 | -92.6 ± 107.07 | -113.3 ± 94.69 |
TIBC, UIBC and Iron were used as marker of iron metabolism and utilization. Baseline was defined as the value on Day 1. CFB was calculated by subtracting the Baseline value from the post-dose value at Week 4.
| micromoles/liter | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| CFB in TIBC at Week 4 | 0.2 ± 1.97 | 8.6 ± 3.96 | 14.4 ± 6.79 | 14.3 ± 5.67 | 17.2 ± 4.87 |
| CFB in UIBC at Week 4 | 0.8 ± 6.10 | 11.7 ± 6.61 | 19.2 ± 9.17 | 16.3 ± 9.18 | 22.1 ± 7.65 |
| CFB in Iron at Week 4 | 0.0 ± 4.46 | -3.1 ± 4.96 | -4.8 ± 5.86 | -2.4 ± 7.16 | -4.9 ± 5.32 |
Transferrin was used as marker of iron metabolism and utilization. Baseline was defined as the value on Day 1. CFB was calculated by subtracting the Baseline value from the post-dose value at Week 4.
| grams/liter | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| CFB in Transferrin at Week 4 | 0.041 ± 0.2013 | 0.449 ± 0.2958 | 0.626 ± 0.3605 | 0.677 ± 0.2948 | 0.804 ± 0.3944 |
TS was used as marker of iron metabolism and utilization. Baseline was defined as the value on Day 1. Percent CFB was calculated as 100 multiplied by the exponential mean change on a log scale minus 1.
| Percent change | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| Percent CFB in Transferrin Saturation (TS) at Week 4 | 1.3 (-10.5 to 14.6) | -31.3 (-41.4 to -19.5) | -45.3 (-54.9 to -33.8) | -35.2 (-50.9 to -14.5) | -50.4 (-59.0 to -39.8) |
Blood samples for plasma pharmacokinetic analysis were collected at Week 4 (pre-dose, 1, 2, 3 hours post-dose). Individual plasma GSK1278863 and M-GSK2391220, GSK2487818, GSK2506102, GSK2531398, GSK2531401, GSK2531403 concentrations have been presented.
| micrograms/liter | Placebo | GSK1278863 4 Milligrams (mg) | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| GSK1278863,Week 4,Pre-dose | — | 0.051 ± NA | 0.031 ± NA | 0.054 ± NA | 0.767 ± NA |
| GSK1278863,Week 4,1 hour Post-dose | — | 57.974 ± 86.6158 | 44.463 ± 64.5550 | 69.804 ± 104.4868 | 105.200 ± 109.5148 |
| GSK1278863,Week 4,2 hour Post-dose | — | 79.718 ± 68.6691 | 88.600 ± 97.6852 | 90.774 ± 95.5198 | 145.487 ± 148.5738 |
| GSK1278863,Week 4,3 hour Post-dose | — | 47.629 ± 38.0349 | 86.753 ± 73.4615 | 82.612 ± 91.3694 | 111.182 ± 104.4788 |
| GSK2391220-M,Week 4,Pre-dose | — | 3.023 ± 2.4591 | 3.357 ± 1.8819 | 5.630 ± 6.2908 | 8.553 ± 8.1226 |
| GSK2391220-M,Week 4,1 hour Post-dose | — | 2.105 ± 1.5209 | 2.883 ± 1.9924 | 4.340 ± 4.0699 | 8.417 ± 7.7174 |
| GSK2391220-M,Week 4,2 hour Post-dose | — | 4.596 ± 3.2987 | 5.809 ± 4.6207 | 9.294 ± 7.6842 | 14.017 ± 10.5152 |
| GSK2391220-M,Week 4,3 hour Post-dose | — | 6.444 ± 4.2038 | 8.227 ± 4.9024 | 11.116 ± 7.5314 | 17.216 ± 9.7376 |
| GSK2487818-M,Week 4,Pre dose | — | 0.141 ± NA | 0.171 ± 0.1193 | 0.336 ± 0.6143 | 1.714 ± 5.1050 |
| GSK2487818-M,Week 4,1 hour Post-dose | — | 0.838 ± 1.0098 | 1.445 ± 1.9773 | 1.633 ± 2.4994 | 4.967 ± 6.2427 |
| GSK2487818-M,Week 4,2 hour Post-dose | — | 4.005 ± 3.2461 | 4.510 ± 4.4290 | 6.843 ± 6.4944 | 10.749 ± 8.8713 |
| GSK2487818-M,Week 4,3 hour Post-dose | — | 5.548 ± 3.7080 | 6.932 ± 4.5891 | 8.504 ± 5.9293 | 14.311 ± 7.8161 |
| GSK2506102-M,Week 4,Pre-dose | — | 2.016 ± 0.7719 | 2.943 ± 1.0669 | 4.244 ± 2.8092 | 5.670 ± 2.2887 |
| GSK2506102-M,Week 4,1 hour Post dose | — | 1.159 ± 0.6277 | 1.705 ± 0.5636 | 2.473 ± 1.5656 | 3.552 ± 1.7551 |
| GSK2506102-M,Week 4,2 hour Post dose | — | 1.344 ± 0.6015 | 1.851 ± 0.8637 | 2.781 ± 1.6266 | 3.963 ± 2.0477 |
| GSK2506102-M,Week4,3 hour Post dose | — | 1.569 ± 0.7467 | 2.163 ± 1.0410 | 3.045 ± 1.8790 | 4.382 ± 1.9892 |
| GSK2531398-M,Week 4, Pre-dose | — | 0.717 ± 0.5356 | 0.772 ± 0.4409 | 1.478 ± 1.9681 | 2.496 ± 2.9738 |
| GSK2531398-M,Week 4,1 hour Post-dos | — | 0.593 ± 0.4255 | 0.828 ± 0.6670 | 1.455 ± 1.7174 | 2.820 ± 2.8853 |
| GSK2531398-M,Week 4,2 hour Post-dose | — | 1.715 ± 1.3986 | 2.141 ± 1.8332 | 3.496 ± 3.0818 | 5.318 ± 4.1121 |
| GSK2531398-M,Week 4,3 hour Post-dose | — | 2.596 ± 1.5630 | 3.328 ± 2.1302 | 4.813 ± 3.4315 | 6.861 ± 3.7679 |
| GSK2531401-M,Week 4, Pre-dose | — | 6.698 ± 3.9349 | 11.849 ± 6.4817 | 17.427 ± 11.3934 | 19.014 ± 7.8014 |
| GSK2531401-M,Week 4,1 hour Post-dose | — | 3.426 ± 2.0445 | 6.383 ± 3.0760 | 9.259 ± 6.3198 | 11.288 ± 6.2673 |
| GSK2531401-M,Week 4,2 hour Post-dose | — | 3.384 ± 1.6984 | 5.546 ± 2.7423 | 8.910 ± 5.2477 | 11.008 ± 6.8874 |
| GSK2531401-M,Week 4,3 hour Post-dose | — | 3.911 ± 2.3475 | 5.849 ± 2.9144 | 8.864 ± 6.0433 | 11.417 ± 6.2311 |
| GSK2531403-M,Week 4, Pre-dose | — | 5.609 ± 3.6494 | 8.183 ± 3.1169 | 12.703 ± 10.1144 | 16.524 ± 9.9794 |
| GSK2531403-M,Week 4,1 hour Post-dose | — | 3.100 ± 2.0550 | 5.093 ± 1.9872 | 7.607 ± 5.5913 | 11.877 ± 8.2571 |
| GSK2531403-M,Week 4,2 hour Post-dose | — | 4.857 ± 3.1705 | 6.906 ± 4.0374 | 10.755 ± 7.3841 | 15.573 ± 10.2857 |
| GSK2531403-M,Week 4,3 hour Post-dose | — | 6.320 ± 4.1558 | 8.744 ± 4.6123 | 12.119 ± 7.6702 | 18.369 ± 9.0090 |
An AE is defined as any untoward medical occurrence in clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A SAE is defined as any AE which results in death; is life-threatening; requires participant hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event.
| Participants | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| Any AE | 5 | 6 | 8 | 7 | 5 |
| Any SAE | 1 | 0 | 0 | 0 | 0 |
The PCI range was as follows: alkaline phosphates \>= 3 times upper limit of normal range \[ULRR\]), potassium (\>0.5 millimoles/liter below the LLRR or \>1.0 millimoles/liter above the ULRR), phosphate (\>0.323 millimoles/liter above ULRR or below lower limit reference range \[LLRR\]), glucose (\<3.9 or \>22 millimoles/liter), magnesium (\<LLRR or \> 0.3 milimoles/liter above ULRR), lymphocytes \<0.5x LLRR, neutrophils (\<0.5 times LLRR), platelets (80 or \>500 times giga/liter), platelets (80 or \>500 times giga/liter) and leukocytes \>1 x giga/liter below the LLRR or \>5 x GI/L above the ULRR. The participants who had PCI values higher and lower than the reference range have been presented.
| Participants | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| Alkaline phosphatase, Week 4, High | 0 | 1 | 0 | 0 | 0 |
| Potassium, High, Week 2 | 0 | 0 | 0 | 1 | 0 |
| Potassium, High, Week 4 | 1 | 0 | 0 | 1 | 0 |
| Phosphate, High, Week 2 | 1 | 9 | 10 | 7 | 9 |
| Phosphate, High, Week 4 | 2 | 9 | 11 | 8 | 10 |
| Potassium, low, Week 4 | 0 | 0 | 1 | 0 | 0 |
| Potassium, low, Week 2 | 0 | 0 | 1 | 0 | 0 |
| Glucose, Week 2, low | 0 | 1 | 0 | 0 | 0 |
| Magnesium, low, Week 4 | 0 | 0 | 0 | 1 | 0 |
| Magnesium, low, Week 2 | 0 | 0 | 0 | 1 | 0 |
| Lymphocytes, low ,Week 1 | 0 | 0 | 0 | 1 | 0 |
| Lymphocytes, low ,Week 3 | 0 | 0 | 1 | 0 | 0 |
| Neutrophils, low, Week 1 | 0 | 1 | 0 | 0 | 0 |
| Platelets, low, Week 1 | 0 | 0 | 1 | 0 | 0 |
| Platelets, low, Week 2 | 0 | 0 | 1 | 0 | 0 |
| Platelets, low, Week 3 | 0 | 0 | 1 | 0 | 0 |
| Platelets, low, Week 4 | 0 | 0 | 1 | 0 | 0 |
| Leukocyte, low, Week 1 | 3 | 3 | 2 | 1 | 2 |
| Leukocyte, low, Week 2 | 2 | 3 | 2 | 4 | 3 |
| Leukocyte, low, Week 3 | 3 | 2 | 0 | 2 | 3 |
| Leukocyte, low, Week 4 | 1 | 2 | 2 | 2 | 4 |
Vital signs SBP and DBP were recorded pre-dialysis and post-dialysis. Measurements were taken from the participant while in a seated position or semi-supine in the dialysis chair. PCI range for SBP was \< 85 or \> 170 and for DBP was \< 45 or \> 100 millimeters of mercury. Participant's with values high and low from the PCI range have been presented.
| Participants | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| DBP, high, Pre-dialysis, Week 1 | 1 | 0 | 1 | 0 | 1 |
| DBP, high, Pre-dialysis, Week 2 | 2 | 0 | 1 | 0 | 2 |
| DBP, high, Pre-dialysis,Week 4 | 0 | 1 | 0 | 0 | 0 |
| DBP, high, Post-dialysis, Week 2 | 1 | 1 | 0 | 0 | 1 |
| DBP, high, Post-dialysis, Week 3 | 0 | 0 | 1 | 0 | 0 |
| DBP, high, Post-dialysis, Week 4 | 0 | 0 | 1 | 0 | 0 |
| DBP, low, Post-dialysis, Week 4 | 1 | 0 | 0 | 0 | 0 |
| SBP, high, Pre-dialysis, Week 1 | 2 | 4 | 0 | 3 | 1 |
| SBP, high, Pre-dialysis, Week 2 | 4 | 3 | 3 | 2 | 4 |
| SBP, high, Pre dialysis, Week 3 | 2 | 3 | 2 | 2 | 1 |
| SBP, high, Pre-dialysis, Week 4 | 2 | 6 | 1 | 4 | 2 |
| SBP, high, Post-dialysis, Week 1 | 4 | 1 | 0 | 1 | 1 |
| SBP, high, Post-dialysis, Week 2 | 1 | 0 | 0 | 1 | 3 |
| SBP, high, Post-dialysis, Week 3 | 2 | 0 | 3 | 2 | 3 |
| SBP, high, Post-dialysis, Week 4 | 1 | 1 | 1 | 2 | 3 |
| SBP, low, Post-dialysis, Week 2 | 0 | 1 | 0 | 0 | 0 |
| SBP, low, Post-dialysis, Week 4 | 1 | 0 | 0 | 0 | 0 |
Vital sign HR was recorded pre-dialysis and post-dialysis. Measurements were taken from the participant while in a seated position or semi-supine in the dialysis chair. PCI range for HR was \< 40 or \> 110 beats per minute. Participant's with values higher than the PCI range have been presented.
| Participants | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| HR, high, Post-dialysis, Week 1 | 0 | 0 | 1 | 0 | 0 |
| HR, high, Post-Dialysis, Week 3 | 0 | 0 | 1 | 0 | 0 |
Full 12-lead ECGs included heart rate, PR, QRS, QT and QTc intervals. Measurements were taken from the participant while in a supine position. ECGs were performed consistently either before or after dialysis throughout the study. ECG abnormalities characterized as abnormal-not clinically significant (A-NCS) and abnormal-clinically significant (A-CS) upto W4 have been presented.
| Participants | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| A-NCS, Week 2 | 5 | 8 | 6 | 7 | 7 |
| A-NCS, Week 4 | 2 | 8 | 5 | 8 | 6 |
Collected over AEs were assessed from screening (Week 3-9) throughout the treatment period (4 Week) until follow-up (4 Weeks post the last dose of study medication).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/19 (0%) | 1/19 (5.3%) | 4/19 (21.1%) |
| GSK1278863 4 mg | 0/19 (0%) | 0/19 (0%) | 6/19 (31.6%) |
| GSK1278863 6 mg | 0/20 (0%) | 0/20 (0%) | 8/20 (40%) |
| GSK1278863 8 mg | 0/19 (0%) | 0/19 (0%) | 7/19 (36.8%) |
| GSK1278863 10 mg | 0/20 (0%) | 0/20 (0%) | 5/20 (25%) |
| Event | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| Cerebral haemorrhageNervous system disorders | 1/19 | 0/19 | 0/20 | 0/19 | 0/20 |
| Event | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 0/19 | 1/19 | 0/20 | 2/19 | 2/20 |
| Upper respiratory tract infectionInfections and infestations | 0/19 | 1/19 | 0/20 | 0/19 | 0/20 |
| DermatitisSkin and subcutaneous tissue disorders | 1/19 | 1/19 | 0/20 | 1/19 | 0/20 |
| Haemorrhage subcutaneousSkin and subcutaneous tissue disorders | 0/19 | 1/19 | 0/20 | 0/19 | 0/20 |
| RashSkin and subcutaneous tissue disorders | 1/19 | 0/19 | 0/20 | 0/19 | 0/20 |
| InjuryInjury, poisoning and procedural complications | 0/19 | 0/19 | 0/20 | 1/19 | 0/20 |
| Procedural hypotensionInjury, poisoning and procedural complications | 0/19 | 1/19 | 0/20 | 0/19 | 0/20 |
| Back painMusculoskeletal and connective tissue disorders | 0/19 | 0/19 | 1/20 | 1/19 | 0/20 |
| Lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 0/19 | 1/19 | 0/20 | 0/19 | 0/20 |
| StomatitisGastrointestinal disorders | 0/19 | 0/19 | 0/20 | 1/19 | 0/20 |
| Age, Continuous(Years) | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 63.4 ± 8.98 | 61.6 ± 8.49 | 58.9 ± 9.90 | 66.0 ± 9.23 | 62.2 ± 11.13 | 62.4 ± 9.70 |
| Sex: Female, Male(Participants) | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | Total |
|---|---|---|---|---|---|---|
| Female | 7 | 11 | 8 | 12 | 9 | 47 |
| Male | 12 | 8 | 12 | 7 | 11 | 50 |
| Race (NIH/OMB)(Participants) | Placebo | GSK1278863 4 mg | GSK1278863 6 mg | GSK1278863 8 mg | GSK1278863 10 mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 19 | 19 | 20 | 19 | 20 | 97 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Nov 2013 to primary completion in Aug 2014, 9 months.
Results were first posted in Feb 2018, 3 years 6 months after primary completion.
Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 9 months is below that.
Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GSK1278863